Pelthos Therapeutics
PTHS | AMEX
$7.15
-$0.29 (-3.90%)
At close: Nov 16, 2026, 4:00 PM ET
$7.15
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
-3.90%
(1D)No price chart data available for 1D timeframe.
Rating
31.2
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #768/1021 (Top 75%)
Key Statistics
Market Data
Market Cap $28.1M
1D Range
7.08 7.81
52W Range
7.08 33.30
Valuation (TTM)
PE -0.38
PB -4.54
EV/EBITDA -1.46
Valuation (NTM)
Forward PE 18.56
Forward PEG -0.23
Price Target $35.00
Cash Flow
FCF Yield -115.9%
SBC Adj. FCF Yield -122.8%
SBC Impact -6.0%
Margins
Gross Margin 68.2%
Operating Margin -101.6%
FCF Margin -63.5%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
142.6%
Dil EPS 3Y | 5Y -31.1% |
-48.8%
FCF 3Y | 5Y -110.5% |
N/A
Returns
ROA -49.1%
ROE -381.4%
ROIC -47.9%
Financial Health
Net Debt
$48.22M
Current Ratio 1.78
Interest Coverage -6.26
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primar...
Sector Healthcare
Industry Biotechnology
Employees 92
IPO Date Feb 16, 2024
Website pelthos.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$2.04
Beat +33.77%
YoY:
+61.51% REV
$15.4M
Miss -9.00%
YoY:
+107.87%Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
4
Consensus
Buy
Price Target
$35.00
Upside
+389.51%
Buy (4)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PTHS